KC-5743

293T-mem-cyno-KLK2 Cell Line

×
60334
Home » 293T-mem-cyno-KLK2 Cell Line

Background of 293T-mem-cyno-KLK2 Cell Line

KLK2 encodes kallikrein related peptidase 2 and is also known as hK2. Kallikreins are a subgroup of serine proteases that are clustered on chromosome 19. Members of this family are involved in a diverse array of biological functions. The protein encoded by this gene is a highly active trypsin-like serine protease that selectively cleaves at arginine residues. This protein is primarily expressed in prostatic tissue and is responsible for cleaving pro-prostate-specific antigen into its enzymatically active form. This gene is highly expressed in prostate tumor cells and may be a prognostic maker for prostate cancer risk. Alternate splicing results in both coding and non-coding transcript variants.

Specifications

Catalog NumberKC-5743
Cell Line Name293T-mem-cyno-KLK2 Cell Line
NCBI/UniProt Accession NumberA0A2K5VYN9
Clone Number9#
Host Cell Line293T
Description293T-mem-cyno-KLK2 is a stable engineered cell line expressing cyno mem-cyno-KLK2
QuantityOne vial of frozen cells (≥2×10⁶ cells/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM+20% FBS+10% DMSO
Propagation MediumDMEM+10%FBS+1μg/mL puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit at a ratio of 1:4–1:6 every 2–3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 19–36 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

293T-mem-cyno-KLK2 cell line was generated using a lentiviral vector expressing the cyno mem-cyno-KLK2 sequence.

Characterization

Figure 1: Characterization of mem cyno KLK2 overexpression in the 293T-mem-cyno-KLK2 stable clone using FACS.

Figure 2: Characterization of mem cyno KLK2 in the 293T stable clone using PCR sequencing.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4–1:6 every 2–3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Koistinen H, Närvänen A, Pakkala M et al. Development of peptides specifically modulating the activity of KLK2 and KLK3. Biological chemistry. 2008 Jun;389(6):633-42. PMID: 18627344. doi: 10.1515/BC.2008.076.
  2. Sayar E, Richards HM, Gulati R et al. Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer. Molecular cancer research : MCR. 2026 Sep 2;24(9):754-769. PMID: 42189191. doi: 10.1158/1541-7786.MCR-26-0052.
  3. McKay RR, Nazari SS, Elliott A et al. Molecular Characterization of KLK2 RNA Expression in Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026 Jun 1;32(11):2293-2304. PMID: 41817312. doi: 10.1158/1078-0432.CCR-25-4293.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.